REFERENCES
- Yeni P. Prise en Charge Medicate des Personnes Infectées pane VIH. Paris: La Documentation Fran&3x00E7;aise; 2010.
- Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International AIDS Society-USA panel. JAMA. 2012;308:387–402.
- Avettand-Fènoël V, Chaix M-L, Blanche S, et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol. 2009;81:217–223.
- Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indina-vir in previously untreated HIV-1-infected patients. Trilage (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med. 1998;339:1269–1276.
- Haylir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med. 1998;339:1261–1268.
- Rouzioux C, Hubert J-B, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis. 2005;192:46–55.
- Lewin SR, Rouzioux C. HIV cure and eradication: How will we get from the laboratory to effective clinical trials ? AIDS. 2011;25:885–897.
- Lambert-Niclot S, Flandre P, Valentin M-A, et al. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis. 2011204: 1211–1216.
- Geretti AM, Arribas JR, Lathouwers E, et al. Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ ritonavir monotherapy versus triple therapy in the MONET trial. HIV Cli n Trials. 2013;14:45–50.
- Hocqueloux L, Avettand-Fenoel V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. [published online ahead of print January 25,2013]. J Antimicrob Chemother.
- Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medica-tion: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther. 2002;7:185–193.